Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 52 points (-0.3%) at 18,381 as of Monday, Aug. 1, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,146 issues advancing vs. 1,771 declining with 163 unchanged.

The Drugs industry currently sits up 0.1% versus the S&P 500, which is down 0.2%. Top gainers within the industry include

Ionis Pharmaceuticals

(

IONS

), up 35.4%,

Alexion Pharmaceuticals

(

ALXN

), up 3.6%,

Regeneron Pharmaceuticals

(

REGN

), up 2.3%,

Illumina

(

ILMN

), up 2.1% and

Bristol-Myers Squibb Company

(

BMY

), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Keryx Biopharmaceuticals

(

KERX

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Keryx Biopharmaceuticals is down $2.26 (-30.7%) to $5.10 on heavy volume. Thus far, 8.5 million shares of Keryx Biopharmaceuticals exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $4.81-$5.35 after having opened the day at $5.16 as compared to the previous trading day's close of $7.36.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Keryx Biopharmaceuticals has a market cap of $778.8 million and is part of the health care sector. Shares are up 45.7% year-to-date as of the close of trading on Friday. Currently there are 7 analysts that rate Keryx Biopharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Keryx Biopharmaceuticals

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally disappointing historical performance in the stock itself and generally high debt management risk. Get the full

Keryx Biopharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

AstraZeneca

(

AZN

) is down $0.25 (-0.7%) to $33.89 on heavy volume. Thus far, 4.4 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 5.6 million shares. The stock has ranged in price between $33.66-$34.07 after having opened the day at $33.66 as compared to the previous trading day's close of $34.14.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of respiratory, inflammation, autoimmune, cardiovascular, metabolic, oncology, infection, neuroscience, and gastrointestinal diseases worldwide. AstraZeneca has a market cap of $86.8 billion and is part of the health care sector. Shares are up 0.6% year-to-date as of the close of trading on Friday. Currently there is 1 analyst that rates AstraZeneca a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

AstraZeneca

as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, notable return on equity, good cash flow from operations and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

AstraZeneca Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Valeant Pharmaceuticals International

(

VRX

) is down $1.32 (-5.9%) to $20.98 on average volume. Thus far, 12.7 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 30.5 million shares. The stock has ranged in price between $20.76-$22.06 after having opened the day at $22.02 as compared to the previous trading day's close of $22.30.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. Valeant Pharmaceuticals International has a market cap of $7.9 billion and is part of the health care sector. Shares are down 78.1% year-to-date as of the close of trading on Friday. Currently there are 4 analysts that rate Valeant Pharmaceuticals International a buy, 3 analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Valeant Pharmaceuticals International

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Valeant Pharmaceuticals International Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).